Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ImmunityBio, Inc. entered into Stock Purchase Agreement with certain institutional investors valued at approximately $50.0 million (effective 2023-02-15).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain institutional investors
- Value
- approximately $50.0 million
- Effective
- 2023-02-15
Exact text from the filing
On February 15, 2023, ImmunityBio, Inc. (the “Company”) entered into a stock purchase agreement (the “SPA”) with certain institutional investors (the “Investors”) for the purchase and sale of 14,072,615 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and warrants to purchase an additional 14,072,615 shares of Common Stock at an exercise price of $4.2636 per share, for a purchase price of $3.5530 per share and accompanying warrant, generating gross proceeds from the offering of approximately $50.0 million before deducting placement agent fees and other estimated offering expenses.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
ImmunityBio, Inc. entered into Placement Agency Agreement with Jefferies LLC (effective 2023-02-15).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Jefferies LLC
- Effective
- 2023-02-15
Exact text from the filing
On February 15, 2023, the Company also entered into a placement agency agreement (the “PAA”) with Jefferies LLC (the “Placement Agent”). Pursuant to the terms of the PAA, the Placement Agent has agreed to serve as our exclusive Placement Agent on a reasonable best efforts basis to arrange for the sale of the securities described above and the Company has agreed to pay the Placement Agent a cash fee equal to 6.0% of the gross proceeds generated from the sale of such securities, less certain Company expenses to be reimbursed by the Placement Agent.
View on SEC.gov